-
Company Insights
Innovation and Patenting activity of CytomX Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CytomX Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CX-904 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CX-904 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CX-904 in Colorectal Cancer Drug Details: CX-904 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CX-904 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CX-904 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CX-904 in Solid Tumor Drug Details: CX-904 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Astegolimab in Chronic Obstructive Pulmonary Disease (COPD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Astegolimab in Chronic Obstructive Pulmonary Disease (COPD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Astegolimab in Chronic Obstructive Pulmonary Disease (COPD) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Fenebrutinib in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fenebrutinib in Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fenebrutinib in Non-Hodgkin Lymphoma Drug Details: Fenebrutinib (GDC-0853, RG-7845) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Fenebrutinib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fenebrutinib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fenebrutinib in Follicular Lymphoma Drug Details: Fenebrutinib (GDC-0853, RG-7845) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pelabresib in Myeloproliferative Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pelabresib in Myeloproliferative Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pelabresib in Myeloproliferative Disorders Drug Details: Pelabresib (CPI-0610) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pelabresib in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pelabresib in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pelabresib in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sovleplenib in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sovleplenib in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sovleplenib in Marginal Zone B-cell Lymphoma Drug Details: Sovleplenib (HMPL-523)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CX-2029 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CX-2029 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CX-2029 in Ovarian Cancer Drug Details: CX-2029 is under development for...